INTENDED FOR UK HEALTHCARE PROFESSIONALS
Trimbow® Logo - beclometasone/formoterol/glycopyrronium (87/5/9 mcg) Extrafine formulation
Background
Trimbow beclometasone/formoterol/glycopyrronium (87/5/9 mcg) Extrafine formulation + Trimbow Device Image

What is Trimbow®?

Trimbow – a logical choice of maintenance treatment to help prevent exacerbations in COPD1

Trimbow is indicated for maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist or a combination of long-acting β2-agonist and long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5.1 of the Trimbow SPC)
Trimbow® Device

Trimbow is:

  • a 3-in-1 pMDI that delivers ICS+LABA+LAMA
  • An extrafine formulation like Fostair® (beclometasone/formoterol)1,2

Each dose contains three compounds for the treatment of COPD:

ICS: Beclometasone
LABA: Formoterol
LAMA: Glycopyrronium

COPD patients who need a combination of ICS/LABA plus a LAMA have traditionally had to deal with multiple inhaler regimens. Trimbow contains an ICS/LABA/LAMA in a single inhaler which may help ease the inhaler burden of COPD.

Each dose contains three compounds for the treatment of COPD:

ICS: Beclometasone
LABA: Formoterol
LAMA: Glycopyrronium

 

COPD Patients who need a combination of ICS/LABA plus a LAMA have traditionally had to deal with multiple inhaler regimens. Trimbow contains an ICS/LABA/LAMA in a single inhaler which may help ease the inhaler burden of COPD.

For additional information to share with your patients who have been prescribed Trimbow please visit our Trimbow patient and carer site.

ICS: inhaled corticosteroid; LABA: long-acting β2-adrenoceptor agonist; LAMA: long-acting muscarinic antagonist.

References:
1. Trimbow Summary of Product Characteristics, Chiesi Limited. Available at: www.medicines.org.uk/emc/product/761
2. Fostair pMDI 100/6 Summary of Product Characteristics, Chiesi Limited. Available at: http://www.medicines.org.uk/emc/product/6318

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Chiesi Limited on 0800 0092329 (UK) or PV.UK@Chiesi.com.

Disclaimer

The purpose of this section of the website is to provide UK healthcare professionals with accurate and relevant information on Chiesi Limited respiratory products.

The contents of this area of the website are intended solely for the use of UK healthcare professionals. If you are NOT a UK healthcare professional, please exit this section of the website.

YES I AM

a UK healthcare professional

NO I'M NOT

a UK healthcare professional

UK-RES-1900858 Jun 2019